No pain, no gain: Will migraine therapies increase bone loss and impair fracture healing?

Kacena, Melissa A.; White, Fletcher A.

doi:10.1016/j.ebiom.2020.103025

Cited by 8 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CGRP is spontaneously released by cultured trigeminal ganglion cells [9], and CGRP is expressed in the perivascular afferents of cranial arteries [10]. Other functions of the CGRP signaling pathway include glucose-insulin regulation, gastrointestinal motility, systemic vasodilation, skin immunity, airway homeostasis, osteoblast, and adipocyte regulations [11,12].…”

Section: Calcitonin Gene-related Peptidementioning

confidence: 99%

Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

Domínguez-Moreno

Phu

Ashina

2022

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

Purpose of reviewTo review the latest advances in migraine management with a focus on medications specifically developed for the treatment of migraine. Recent findingsRandomized clinical trials demonstrated the efficacy of calcitonin gene-related peptide (CGRP) mAbs for the preventive treatment of migraine and the small molecule CGRP receptor antagonist gepants for acute abortion and prevention of migraine attacks. Pituitary adenylate cyclase-activating polypeptide (PACAP) is another signaling molecule of interest and represents a potential new drug class of mechanism-based migraine medications. Drugs targeting PACAP are currently undergoing clinical trials, and the coming years will reveal whether this class of drugs will expand our therapeutic armamentarium. SummaryHere, we summarize the role of CGRP and PACAP in migraine pathophysiology and discuss novel therapies targeting the CGRP and PACAP signaling pathways.

show abstract

Section: Calcitonin Gene-related Peptidementioning

confidence: 99%

Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

Domínguez-Moreno

Phu

Ashina

2022

Current Opinion in Endocrinology, Diabetes &Amp; Obesity

View full text Add to dashboard Cite

show abstract

“…PNS function can also modify the immune response. In addition, changes in peripheral nerve function can alter muscle, behavior, and movement, resulting in local adaptation of the bone due to altered biomechanical loading [ 3 ]. Though complex, these broad potential relationships between the PNS and bone present a unique opportunity for discovery.…”

Section: Introductionmentioning

confidence: 99%

Role of the Peripheral Nervous System in Skeletal Development and Regeneration: Controversies and Clinical Implications

Hassan

Horenberg

Coler‐Reilly

et al. 2023

Curr Osteoporos Rep

View full text Add to dashboard Cite

Purpose of Review This review examines the diverse functional relationships that exist between the peripheral nervous system (PNS) and bone, including key advances over the past century that inform our efforts to translate these discoveries for skeletal repair. Recent Findings The innervation of the bone during development, homeostasis, and regeneration is highly patterned. Consistent with this, there have been nearly 100 studies over the past century that have used denervation approaches to isolate the effects of the different branches of the PNS on the bone. Overall, a common theme of balance emerges whereby an orchestration of both local and systemic neural functions must align to promote optimal skeletal repair while limiting negative consequences such as pain. Summary An improved understanding of the functional bidirectional pathways linking the PNS and bone has important implications for skeletal development and regeneration. Clinical advances over the next century will necessitate a rigorous identification of the mechanisms underlying these effects that is cautious not to oversimplify the in vivo condition in diverse states of health and disease.

show abstract

“…Future studies should attempt to clarify the association between bone turnover and migraine, and further evaluate the possible effect of vitamin D treatment for patients affected by migraine, even if it does not yet have a clear impact on migraine attacks. Moreover, clinicians should consider possible consequences from prophylaxis therapies with topiramate 9 and anti-CGRP 10 in regulating the bone mass.…”

mentioning

confidence: 99%

Elevated Bone Resorption Markers in Patients With Migraine: A Case Series

Lerario¹

2022

J Clin Neurol

View full text Add to dashboard Cite

No pain, no gain: Will migraine therapies increase bone loss and impair fracture healing?

Cited by 8 publications

References 8 publications

Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

Role of the Peripheral Nervous System in Skeletal Development and Regeneration: Controversies and Clinical Implications

Elevated Bone Resorption Markers in Patients With Migraine: A Case Series

Contact Info

Product

Resources

About